Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies

Leukemia Research
Daniel G WrightKristin Waraska

Abstract

Inosine-5'-monophosphate-dehydrogenase (IMPDH) regulates the de novo synthesis of guanine ribonucleotides (GNT). IMPDH activity varies inversely with intracellular [GNT] and is linked to cellular proliferation. K562 leukemia cell growth was studied relative to IMPDH expression and activity following culture of the cells with Tiazofurin, an IMPDH inhibitor. Tiazofurin depressed IMPDH activity and [GTP] in K562 cells, and also increased IMPDH mRNA expression. Following exposure to Tiazofurin, K562 cell proliferation, entry into cycle, and sensitivity to cycle-active cytotoxic agents were increased. These findings indicate that the efficacy of standard chemotherapy in bcr-abl positive leukemias might be enhanced if combined sequentially with Tiazofurin.

References

Nov 1, 1991·Molecular and Cellular Biology·D A GlesneE Huberman
Jul 30, 1985·Biochimica Et Biophysica Acta·H E GruberJ E Seegmiller
Dec 1, 1983·The Journal of Clinical Investigation·D L LucasD G Wright
Mar 24, 1995·The Journal of Biological Chemistry·A G ZimmermannB S Mitchell
Sep 30, 1998·Progress in Nucleic Acid Research and Molecular Biology·A G ZimmermannB S Mitchell
Oct 18, 2000·The Journal of Biological Chemistry·M Escobar-Henriques, B Daignan-Fornier

❮ Previous
Next ❯

Citations

Jul 16, 2010·Leukemia & Lymphoma·Katherine L B Borden, Biljana Culjkovic-Kraljacic
Oct 26, 2005·The Journal of Biological Chemistry·YanShan JiBeverly S Mitchell
Jul 22, 2006·Advances in Enzyme Regulation·Edith OláhMárton Keszei

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.